To achieve hepatocyte-targeted in vivo gene expression, a carrier that controls both the tissue and intracellular distribution of DNA was designed and synthesized. A cationic polymer, poly(L-ornithine) (pOrn), was modified first with galactose, then with a fusigenic peptide (mHA2) to obtain GalpOrn-mHA2. When applied with Gal-pOrn-mHA2 to asialoglycoprotein receptor-positive cells, fluorescein-labeled DNA showed a diffuse profile, suggesting the release of DNA from endosomes and/or lysosomes by the carrier. Then the biodistribution and gene expression after intravenous injection of DNA complexes (10 g DNA per mouse) were examined. After injection of [ 32 P]DNA/Gal-pOrn-mHA2, about 60% of the radioactivity was recovered in the liver, mostly in paren-
Introduction
In vivo gene therapy requires the development of carriers (vectors) which can deliver therapeutic genes to a specific cell population and there, efficiently express encoded proteins. Although viral systems such as retroviral and adenoviral vectors are potentially very efficient, nonviral gene delivery systems have some advantages in that they are less toxic, less immunogenic and easier to prepare. [1] [2] [3] [4] However, the major limitation of nonviral systems has been their low efficiency of gene expression. Therefore, to increase the efficiency of nonviral carriers, materials that can enhance gene expression, such as viruses or viral proteins, [5] [6] [7] [8] [9] fusigenic lipids, 10 and fusigenic, membranedisruptive peptides 11, 12 have been introduced into nonviral carrier systems. To preserve the advantages of nonviral systems, however, only chemically synthetic compounds like fusigenic peptides can be candidates as helper molecules. Although fusigenic peptides are reported strongly to enhance in vitro gene transfer by several DNA/carrier complexes after being incorporated into carrier systems by chemical linkage 11 or by ionic interaction, 12, 13 their application to in vivo gene transfer has not been reported yet. From a pharmacokinetic point chymal cells. A large amount (81 ng/g tissue) of transgene product (luciferase) was detected in the liver of mice injected with DNA/Gal-pOrn-mHA2, which was 280-fold greater than that obtained with DNA/DOTMA:Chol liposomes (50 g DNA). Prior administration of galactosylated albumin reduced the gene expression to 1/100, indicating the asialoglycoprotein receptor-mediated gene transfer in liver parenchymal cells, ie hepatocytes. The luciferase activity in hepatocytes contributed more than 95% of the total activity in all the tissues examined. Thus, hepatocyte-targeted in vivo gene expression was achieved by the intravenous injection of DNA complex with the multifunctional gene carrier. Gene Therapy (2000) 7, 548-555.
of view, they should be firmly attached to carriers by some means such as chemical conjugation.
In addition to expression efficiency, the cell-specificity of gene expression is another important issue for in vivo gene transfer. Among various cells, hepatocytes are substantial targets for gene therapy, because there are many fetal metabolic diseases resulting from defect or deficiency of hepatocyte-derived gene products. 14, 15 In addition, hepatocytes can be considered as platforms to produce various proteins secreted into blood since the liver has a rich blood flow. Therefore, gene delivery systems which can deliver therapeutic genes selectively to hepatocytes in vivo followed by efficient gene expression within the cells is valuable. Cationic liposomes are efficient nonviral carriers, but systemic administration of DNA/cationic liposome complexes result in gene expression in various tissues with the highest expression in the lung in most cases. [16] [17] [18] These features are due to defects in the biodistribution properties of DNA/cationic liposome complexes after systemic (intravenous) administration. 19, 20 They may be coated with serum proteins to form aggregates, or bind nonspecifically to cells such as erythrocytes, lymphocytes and endothelial cells, as well as to extracellular matrix proteins. To solve these problems, ie to achieve improved delivery of DNA to hepatocytes, DNA/carrier complexes are sometimes administered via the portal vein. 21, 22 Although intraportal injection seems to be less invasive than reimplantation of hepatocytes or partial hepatectomy that has been some-times used for ex vivo or in vivo gene transfer, [23] [24] [25] the intravenous route is safer and more convenient than intraportal injection.
Hepatocyte-targeted delivery of DNA would be more easily achieved by polymer-based gene delivery systems having galactose moieties than by particulate gene carriers like cationic liposomes. The asialoglycoprotein receptor-mediated gene targeting hepatocytes using galactosylated polymers has been investigated as a promising approach to introduce genetic materials into hepatocytes in vivo. [26] [27] [28] [29] To achieve hepatocyte-targeted delivery of DNA, however, not only the specific ligands (galactose) but also the overall physicochemical properties of DNA/carrier complexes should be optimized. In previous studies, 30, 31 we have investigated the in vivo pharmacokinetics of DNA/galactosylated poly(L-lysine) (Gal-PLL) complexes and succeeded in delivering them to hepatocytes by controlling the physicochemical properties of the Gal-PLL and DNA/Gal-PLL complexes. However, the in vivo gene expression was not very intense even in the liver.
In this paper, in order to achieve hepatocyte-targeted delivery of DNA and improved gene transfer by intravenous injection of a DNA complex, a multifunctional carrier molecule, galactosylated poly(L-ornithine)-fusigenic peptide conjugate, was chemically synthesized. The functions of this carrier were designed so that it would (1) bind and condense DNA for optimizing systemic disposition profile; (2) deliver DNA to hepatocytes through asialoglycoprotein receptor recognition; and (3) release DNA from endosomes/lysosomes into cytoplasm after internalization. The carrier was mixed with DNA in a hypertonic solution to form DNA complex having a relatively small size, and then the complex was intravenously injected into mice via the tail vein. The biodistribution and gene expression after injection of the complex were examined by monitoring 32 P-radioactivity and luciferase assay, respectively, and compared with data obtained after the injection of DNA complexes with other carriers. As a result, peptide-mediated enhancement in gene expression was realized in hepatocytes after intravenous injection of the complex, and the level of gene expression was much greater than that obtained by the administration of a conventional DNA/cationic liposome complex. To our knowledge, this is the first report demonstrating the usefulness of synthetic fusigenic peptides for in vivo gene transfer and the simultaneous manipulation of both tissue and intracellular distribution of DNA complexes.
Results
Hemolytic activity of fusigenic peptide mHA2 Based on the amino-terminal of influenza virus hemagglutinin subunit HA-2, 13 we designed and synthesized an acid-sensitive fusigenic peptide (modified HA-2; mHA2). When incubated with mouse erythrocytes at pH 5.0, the peptide mHA2 actually induced hemolysis in a concentration-dependent manner (Figure 1 ). However, mHA2 did not show any significant hemolytic activity at pH 7.4, even at the highest concentration of 100 m.
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Physicochemical characteristics of pOrn derivatives and DNA complexes
The numbers of galactose units were determined to be 29 and 18 residues per polymer for Gal-pOrn and Gal-pOrnmHA2, respectively. In Gal-pOrn-mHA2, three molecules of mHA2 were attached per Gal-pOrn. Then, to the 20% sucrose solution of DNA were added these pOrn derivatives to form DNA complexes. The particle size of the DNA complexes was determined to be 110-130 nm, which was a little smaller than that of naked DNA (Table  1) . These values were also smaller than those of DNA complexes in our previous study (about 200 nm) in which the complexes were formed and measured in 0.9% NaCl isotonic solution. a The DNA/pOrn complexes were prepared by adding pOrn derivatives to DNA at a charge ratio of 1:3 (−/+) in 20% sucrose solution.
The particle sizes of DNA and its complexes were measured by a dynamic light scattering spectrophotometer at a concentration of 10 g DNA/ml. DNA in endosomal/lysosomal compartments. However, [Fl]DNA/Gal-pOrn-mHA2 showed a quite different distribution pattern from other complexes with the fluorescence being diffusively distributed within the cytoplasm.
Figure 2 (a) Concentration of
Tissue distribution of [ ]DNA/pOrn, and 50 to 60% of the radioactivity was recovered in the liver. In any case examined, the total radioactivity recovered in the tissues sampled reached only 50 to 78% of the injected dose. Metabolism of [ 32 P]DNA followed by the distribution of low-molecular weight radioactive metabolites to tissues like muscle might explain the discrepancy of the recovered radioactivity.
The liver cells of mice injected with [ 32 P]DNA/GalpOrn-mHA2 were separated into parenchymal cells (PC) and NPC by collagenase perfusion and the 32 P-radioactivity was largely recovered in the PC fraction ( Figure   3a ). The ratio of the radioactivity in PC and NPC (PC/NPC) on a cell-number basis was calculated to be 4.4, indicating that DNA can be preferentially delivered to hepatocytes by Gal-pOrn-mHA2.
In vivo gene expression after intravenous injection
After injection of 10 g naked DNA, luciferase activity was scarcely detected in any tissue examined (Figure 4) . Although efficient gene expression has been reported after intraportal administration of naked DNA in a hypertonic solution, 22 in the present study, such enhancement in gene expression was not observed after intravenous injection of DNA.
As shown in Figure 4 , the complex formation with pOrn (DNA/pOrn) had no effect on the level of gene expression in any tissue. However, the administration of DNA/Gal-pOrn resulted in a relatively high gene expression in the liver. Luciferase activity in the liver was 0.26 ng/g tissue on average, which was several hundredfold greater than that with DNA and DNA/pOrn. Although luciferase activity was also found in the lung, the level was much lower than that detected in the liver. The use of Gal-pOrn-mHA2 as a DNA carrier drastically increased the mean luciferase level in the liver to 81 ng/g liver. This value was about 100 000-fold and 300-fold as large as that of naked DNA and DNA/Gal-pOrn, respectively. Although luciferase activity was also detected in other tissues, it was at least 14 000-fold lower than that in the liver. In addition, the gene expression in the liver was dose-dependent and a significant gene expression could be detected in the liver at the dose of as low as 1 g per mouse ( Figure 5 ). However, increasing the dose also augmented the gene expression in other tissues such as the lung. As shown in Figure 5 , liver to lung ratio, calculated as a parameter indicating the liver specificity of the gene expression, decreased with the increase in the dose.
The gene expression level of DNA/Gal-pOrn-mHA2 was compared with that of the DNA/DOTMA:Chol liposome complex (Figure 4) . The administered dose of DNA/DOTMA:Chol liposome complex was fixed at 50 g DNA per mouse, a 5 × greater than that of other cases in this study, because the administration of Gene Therapy DNA/DOTMA:Chol liposome complex at a dose of 10 g DNA per mouse did not result in a significant gene expression in any tissue examined. In this case, luciferase activity was highest in the lung with an average value of 4.8 ng/g tissue, followed by that in the liver (0.29 ng/g tissue). Therefore, the activity in the liver obtained by intravenous injection of DNA/Gal-pOrn-mHA2 (10 g DNA) was about 280-fold greater than that with 50 g DNA in the form of DNA/DOTMA:Chol liposome, one of the common cationic liposome formulations used for in vitro and in vivo gene transfer.
To confirm the cells expressing luciferase protein, the liver cells of mice injected with DNA/Gal-pOrn-mHA2 were separated into PC and NPC fractions. More than 11-fold greater luciferase activity was detected in PC than in NPC on a cell-number basis (Figure 3b) .
Duration of the gene expression by an intravenous injection of DNA/Gal-pOrn-mHA2 was also examined. When determined at 1, 3, 6 h, 1, 2, 4 and 7 days after injection, the gene expression in the liver peaked at 6 h after injection, then decreased with time to an undetectable level at 4-7 days ( Figure 6 ). However, a second injection of DNA/Gal-pOrn-mHA2 with an interval of 7 days increased the gene expression in the liver to the peak level obtained by its first injection.
Effect of preadministration of Gal-BSA Figure 7 shows the luciferase activity in organs of mice injected with DNA/Gal-pOrn-mHA2, with or without predosing of galactosylated bovine serum albumin (Gal-BSA). Gal-BSA, a well-known ligand for the asialoglycoprotein receptors, was injected at a dose of 10 mg/kg, which is enough to saturate receptor-mediated endocytosis. 33, 34 The pre-administration of Gal-BSA markedly reduced the gene expression in the liver by a factor of about 100, indicating a significant contribution by asialoglycoprotein receptor-mediated endocytosis to gene expression after intravenous injection of DNA/Gal-pOrnmHA2 complex. Gene expression in other tissues was hardly affected by administration of Gal-BSA. 
Discusssion
In vivo gene expression will take place only at restricted cells that are reached by intact DNA after administration. After systemic (intravenous) administration, DNA is taken up by limited types of cells because DNA hardly passes through the layer of endothelial cells in most tissues due to its large size. Only the capillaries in the liver, spleen and bone marrow possess pores and intercellular junctions 35 that allow DNA and its complexes to distribute into interstitial spaces and reach parenchymal cells. Therefore, in addition to endothelial cells, parenchymal cells of tissues like hepatocytes can be targets for systemic DNA delivery.
Naked DNA possesses particular physicochemical characteristics such as a large molecular weight and a strong negative charge, which results in its rapid uptake by liver nonparenchymal cells, like Kupffer cells, via scavenger receptor-like mechanisms. 32, 36 Since the pioneer work by Wu and Wu, 26,27 the asialoglycoprotein receptor-mediated gene targeting to hepatocytes has been investigated as a promising approach to introduce genetic material into hepatocytes in vivo. This strategy is based on the utilization of asialoglycoproteins or galactose moieties as homing devices to hepatocytes, and of cationic polymers as 'carriers' that noncovalently bind negatively charged DNA and the homing devices. To achieve a hepatocyte-directed delivery of DNA, however, a DNA/carrier complex should reach the target, ie hepatocytes. Therefore, the complex should be small enough to pass through the fenestrae and be negatively charged so as not to interact with various tissues nonspecifically. Based on these considerations, we have examined the delivery of DNA to hepatocytes by changing the physicochemical properties of a carrier, Gal-PLL, and of the DNA/carrier complexes. 30, 31 Controlling these properties resulted in the successful delivery of [ 32 P]DNA to hepatocytes, but gene expression in the liver was inadequate. One obstacle was the limited solubility of the complexes in isotonic solutions. Perales et al 37 reported that concentrated NaCl solutions could prevent the precipitation of DNA/cationic polymer complexes and reduce their size. However, in our studies, a concentrated NaCl solution was toxic to mice and could not be applied to in vivo studies. Instead, a 20% sucrose solution was used for the preparation of the DNA complexes. This sucrose solution was effective in increasing the solubility of the complexes and a solution with a concentration of 50 g DNA/ml could be obtained. Furthermore, the sizes of complexes prepared in this solution were smaller than those prepared in an isotonic solution. This reduction in size should be beneficial to the targeting of DNA to hepatocytes. In fact, [
32 P]DNA complex administered in hypertonic solution was more efficiently delivered to liver PC (PC/NPC ratio of 4.4) than when administered in saline (the ratio of about 2). 30 Although receptor-mediated endocytosis is a useful mechanism for selectively and efficiently delivering DNA into a specific type of cells, the transfection efficiency was found to be severely reduced because of the lysosomal degradation of endocytosed ligand. To improve the gene expression level of these approaches, peptides that destroy biological membranes have been synthesized and introduced into gene delivery systems. 38 The newly developed peptide, mHA2, was designed based on the report of Plank et al; 13 the peptide has the same sequence as INF7 except for cystein on the carboxyl-terminal (instead of glycine for INF7). This replacement of glycine with cystein allowed us to covalently bind the peptide to the carrier through a disulfide bond. Although other functional groups of the peptide, such as carboxyl and amino groups, were available for conjugation, these groups remained unchanged since they are important for the fusigenic activity of the peptide. In previous in vitro studies, fusigenic peptides were incorporated into delivery systems by conjugation 11 or ionic binding. 12, 13 However, for in vivo application, peptides covalently bound to delivery systems would be desirable to exert their activity at the target site. In fact, gene expression following the injection of the DNA complex with Gal-pOrn and mHA2 (ionically bound) was about one-tenth that of the DNA complex with Gal-pOrn-mHA2 (data not shown), supporting the importance of the covalent binding of the peptide to the carrier.
Cationic liposomes are efficient nonviral gene delivery systems that can be applied to in vivo studies. 18, 39, 40 However, it is very difficult to control the biodistribution of DNA/cationic liposome complexes after systemic administration. Although only about 60% of 32 P-radioactivity was recovered in the liver after intravenous injection of [ 32 P]DNA/Gal-pOrn-mHA2, the liver was almost responsible for the total luciferase activity obtained. Furthermore, the gene expression in the liver was highly preferential for PC with a PC/NPC ratio of 11, whereas distribution of the radioactivity was not so cell-specific with a ratio of 4.4. Biodistribution of radioactive metabolites should be involved in the distribution of 32 P-radioactivity after injection of [ 32 P]DNA complexes, and this might explain the difference between the distribution of the radioactivity and gene expression. Also, the efficiency of gene transfer by the DNA complex could depend on the types of cells.
Long-term expression is often required for gene therapy of hereditary diseases. Gene expression by an intravenous injection of DNA/Gal-pOrn-mHA2 peaked at 6 553 h after injection, then decreased with time to an undetectable level at 4-7 days. However, a second injection of the complex with an interval of 7 days increased the gene expression in the liver to the peak level obtained by its first injection. Therefore, multiple administration of the complex could be possible to maintain a high level of gene expression. Recently, Lö ser et al 41 reported that the CMV promoter is transcriptionally inactivated in the mouse liver after adenoviral transduction, probably due to the decrease of the transcription factor NFB. Thus, more prolonged gene expression could be achieved by changing the CMV promoter.
In conclusion, taking both the tissue and intracellular distribution of DNA complexes into consideration, we successfully developed a multifunctional DNA carrier, Gal-pOrn-mHA2, which was highly effective in producing hepatocyte-preferential in vivo gene expression by intravenous injection. The multifunctional carrier would be a powerful tool for in vivo delivery of genes encoding therapeutic proteins into hepatocytes. Animals ICR mice (female, 25-28 g) were purchased from the Shizuoka Agricultural Co-operative Association for Laboratory Animals (Shizuoka, Japan) and were maintained on standard food and water under conventional housing conditions.
Materials and methods

Chemicals
Preparation of DNA pCMV-Luc was constructed by subcloning the HindIII/XbaI firefly luciferase cDNA fragment from pGL3-control vector (Promega, Madison, WI, USA) into the polylinker of pcDNA3 vector (Invitrogen, Carlsbad, CA, USA). DNA was amplified in the E. coli strain DH5␣, isolated, and purified using a QIAGEN Plasmid Giga Kit (QIAGEN, Hilden, Germany). Purity was confirmed by 1% agarose gel electrophoresis followed by ethidium bromide staining and the DNA concentration was measured by UV absorption at 260 nm. DNA was labeled with [␣-32 P]dCTP by nick translation 42 for the biodistribution experiment, or with fluorescein using a Fast-Tag FL labeling kit (Vector Laboratories, Burlingame, CA, USA) for the confocal microscopic study.
Synthesis of Gal-pOrn pOrn was used as a carrier backbone instead of the previously used PLL, since our preliminary results indicated Gene Therapy its usefulness in the formation of DNA complexes. GalpOrn was synthesized by the same procedure as reported for the synthesis of Gal-PLL. 30 The number of galactose residues was determined by the anthrone-sulfuric acid method.
Synthesis of fusigenic peptide
A peptide having acid-sensitive fusigenic activity with the sequence GLFEAIEGFIENGWEGMIDGWYC, a derivative of the amino-terminal of influenza virus hemagglutinin subunit HA-2 (modified HA-2; mHA2), was synthesized by the fluoren-9-ylmethoxycarbonyl (Fmoc) procedure 43 using an Applied Biosystems 433A peptide synthesizer (Perkin Elmer Biosystems, Foster City, CA, USA). The peptide was cleaved from the resin and the side-chain protecting groups were removed by stirring in water/m-cresol/thioanisole/1,2-ethanedithiol/ trifluoroacetic acid (1:1:1:1:16) for 2 h at room temperature. The peptide obtained was washed three times with cold ether, dried under N 2 , and stored below −20°C until use.
Erythrocyte lysis assay
In vitro hemolytic activity of mHA2 was investigated using mouse erythrocytes according to a reported method 13 with a slight modification. Erythrocytes collected from mice were washed with and suspended in phosphate-buffered saline (PBS), pH 5.0 or 7.4, at a concentration of approximately 7 × 10 7 cells/ml. To an aliquot of the cell suspension was added a varying amount of mHA2, and the cell suspension was incubated for 1 h at 37°C with gentle shaking. After removal of the unlyzed erythrocytes by centrifugation, a portion of the supernatant was used to assay the hemoglobin concentration by photometric determination at 450 nm.
Attachment of mHA2 to Gal-pOrn mHA2 was covalently attached to Gal-pOrn using the heterobifunctional reagent, SPDP. To a solution of GalpOrn in 75 mm sodium acetate buffer (pH 8.5) was added a three-fold molar excess of SPDP. After extensive stirring for 1 h at room temperature, the reaction was terminated by the addition of 1 m sodium acetate (pH 5), and impurities were removed by gel-filtration chromatography using a PD-10 column (Pharmacia, Uppsala, Sweden). A 10-fold molar excess of mHA2 was added to the solution of SPDP-coupled Gal-pOrn under N 2 , and then the reaction proceeded for 18 h at room temperature. The number of peptide residues attached to Gal-pOrn was calculated by measuring the absorbance at 344 nm which correlates with the concentration of the byproduct of the reaction, pyridine-2-thione (⑀ = 8.08 × 10 3 ). The final product, Gal-pOrn-mHA2, was purified using a PD-10 column and lyophilized.
Formation of DNA complexes Except for confocal microscopic experiments, DNA complexes were prepared in 20% (w/v) sucrose solution by adding pOrn, Gal-pOrn, or Gal-pOrn-mHA2 to DNA followed by brief stirring at room temperature. The charge ratio was fixed at 1:3 (−/+) for all preparations, which is approximately 1:1.8 on a weight basis. In the case of DNA/Gal-pOrn-mHA2, Gal-pOrn-mHA2 diluted with the same amount of Gal-pOrn was used for the preparations, ie 10 g DNA was mixed with 9 g each of Gal-pOrn-mHA2 and Gal-pOrn. The particle size of the DNA complexes was measured in a dynamic light scattering spectrophotometer (LS-900, Otsuka Electronics, Osaka, Japan).
Confocal microscopic study
Human hepatoma HepG2 cells, purchased from Dainippon Pharmaceutical (Osaka, Japan) were cultured in Dulbecco's modified Eagle's medium (DMEM, Nissui Pharmaceutical, Tokyo, Japan) plus 10% heat-inactivated fetal bovine serum (BioWhittaker, Walkersville, MD, USA) and penicillin-streptomycin-glutamine (GIBCO, Renfrewshire, UK). The cells were seeded on glass plates and grown for 1 day. Then, the culture medium was removed and 3 g fluorescein-labeled DNA ([Fl]DNA) or its complexes dissolved in OPTI-MEM (GIBCO) was added. After a 2 h incubation at 37°C under 5% CO 2 , the cells were washed three times with ice-cold OPTI-MEM and fixed with phosphate-buffered saline containing 4% paraformaldehyde and 0.01% glutaraldehyde for 20 min at 4°C. Then, the cells were washed three times with saline, and scanned with a confocal laser microscope MRC-1024 (Nippon BioRad Laboratories, Tokyo, Japan). ]DNA or its complex with any pOrn derivative. At 2, 5, 10 and 30 min after injection, groups of three mice each were anesthetized with ether and blood was collected from the vena cava to obtain plasma by centrifugation at 2000 g for 2 min. The liver, kidney, spleen, lung and heart were excised, rinsed with saline and weighed. These organs were homogenized with 0.05% Triton X-100 solution and samples were used to determine 32 P-radioactivity.
In vivo gene expression after intravenous injection of DNA complexes
In most experiments, mice were injected with 10 g DNA or its complex. At 6 h after injection, mice were killed and the liver, kidney, spleen, lung and heart were collected, washed with saline and weighed. In experiments examining the duration of gene expression, the tissues were collected at different periods after injection. These organs were homogenized with a five-fold excess of a lysis buffer (0.05% Triton X-100, 2 mm EDTA, 0.1 m Tris, pH 7.8). Then the homogenates were subjected to three cycles of freezing and thawing, and centrifuged at 10 000 g for 3 min at 4°C. The supernatant was used to measure luciferase activity.
To compare the gene expression level of DNA complexes with pOrn derivatives, a DNA/cationic liposome complex was also injected into mice and the luciferase activity in tissues was determined. To this end, 50 g DNA complexed with 500 g DOTMA:Chol liposome (charge ratio, 1:2.8 (−/+)) in 5% glucose solution was injected into mice, and gene expression was examined 6 h after injection.
Pre-administration of Gal-BSA To examine the involvement of asialoglycoprotein receptor-mediated uptake in gene expression in the liver, Gal-BSA (10 mg/kg) was administered to mice 5 min before the injection of DNA/Gal-pOrn-mHA2. Then, the luciferase activity in tissues was determined.
Isolation of liver PC and NPC after intravenous injection of DNA/Gal-pOrn-mHA2 Mice received an injection of DNA (or [ 32 P]DNA)/GalpOrn-mHA2, and were anesthetized by peritoneal administration of pentobarbital sodium. At 10 min after injection, the liver cells were separated into parenchymal cells (PC) and nonparenchymal cells (NPC) as reported previously. 30 In brief, the liver was perfused with HEPES buffer (pH 7.5) containing collagenase. The dispersed cells were separated into PC and NPC fractions by differential centrifugation. These cell fractions underwent 32 Pradioactivity assay for the [ 32 P]DNA complex, or luciferase assay for DNA complex. To measure the luciferase activity, cell suspensions were subjected to three cycles of freezing (liquid N 2 for 3 min) and thawing (37°C for 3 min), followed by centrifugation at 10 000 g for 3 min.
Measurement of 32
P-radioactivity An aliquot of each sample was dissolved with Soluene-350 (Packard, The Netherlands), and scintillation medium (Clear-sol I; Nacalai Tesque, Kyoto, Japan) was added. The 32 P-radioactivity was counted using an LSC-5000 liquid scintillation counter (Beckman, Tokyo, Japan).
Measurement of luciferase activity
Ten microliters supernatant of tissue or cellular homogenate was mixed with 100 l luciferase assay buffer (Picagene; Toyo Ink, Tokyo, Japan) and the light produced was immediately measured using a luminometer (Lumat LB 9507, EG&G Berthold, Bad Wildbad, Germany). Conversion from relative light units to luciferase protein mass was carried out using a standard curve (10 −3 to 10 2 pg), which was corrected for tissue quenching by measuring luciferase protein standards in tissue extracts from untreated control animals. The detection limit was set at 0.0003 ng/g tissue (120 relative light units (RLU)/10 l sample, the blank level was about 50 RLU) in any tissue sample.
